Shares of Depomed (DEPO) are sinking after the company announced that an FDA panel had voted 12-2 against recommending approval of the company's drug for the treatment of hot flashes caused by menopause. Depomend added this afternoon that it would halt all spending on the drug, which is known as Sefelsa. Depomed said it believes that the hurdles to FDA approval of Sefelsa remain high. Depomed's stock was halted for trading from the market open until several minutes ago. In mid-afternoon trading, the stock sank 65c, or 9.65%, to $5.90.